title: Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy.
abstract: Standard cancer treatments trigger immune responses that may influence tumor control. The nature of these responses varies depending on the tumor and the treatment modality. We previously reported that radiation and androgen-deprivation therapy (ADT) induce tumor-associated autoantibody responses in prostate cancer patients. This follow-up analysis was conducted to assess the relationship between autoantibody responses and clinical outcome. Patients with non-metastatic prostate cancer received external beam radiation therapy (EBRT) plus neoadjuvant and concurrent androgen deprivation. Treatment-induced autoantibodies were detected in almost a third of patients receiving combinatorial ADT and EBRT. Unexpectedly, patients that developed autoantibody responses to tumor antigens had a significantly lower 5-year biochemical failure-free survival (BFFS) than patients that did not develop an autoantibody response. Thus, tumor-reactive autoantibodies may be associated with increased risk of biochemical failure and immunomodulation to prevent autoantibody development may improve BFFS for select, high-risk prostate cancer patients receiving both ADT and EBRT.
authors.affiliation: Trev and Joyce Deeley Research Centre; Victoria, BC Canada.
authors.forename: Lisa Ds
authors.initials: LD
authors.lastname: Johnson
authors.affiliation: Trev and Joyce Deeley Research Centre; Victoria, BC Canada.
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Nesslinger
authors.affiliation: Radiation Oncology; BC Cancer Agency; Victoria, BC Canada.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Blood
authors.affiliation: Trev and Joyce Deeley Research Centre; Victoria, BC Canada.
authors.forename: Navraj
authors.initials: N
authors.lastname: Chima
authors.affiliation: Trev and Joyce Deeley Research Centre; Victoria, BC Canada.
authors.forename: Lindsay R
authors.initials: LR
authors.lastname: Richier
authors.affiliation: Radiation Oncology; BC Cancer Agency; Victoria, BC Canada.
authors.forename: Charles
authors.initials: C
authors.lastname: Ludgate
authors.affiliation: Radiation Oncology; BC Cancer Agency; Victoria, BC Canada.
authors.forename: Howard H
authors.initials: HH
authors.lastname: Pai
authors.affiliation: Radiation Oncology; BC Cancer Agency; Victoria, BC Canada.
authors.forename: Jan T
authors.initials: JT
authors.lastname: Lim
authors.affiliation: Trev and Joyce Deeley Research Centre; Victoria, BC Canada ; Department of Biochemistry and Microbiology; University of Victoria; Victoria, BC Canada ; Department of Medical Genetics; University of British Columbia; Vancouver, BC Canada.
authors.forename: Brad H
authors.initials: BH
authors.lastname: Nelson
authors.affiliation: Radiation Oncology; BC Cancer Agency; Victoria, BC Canada ; Department of Surgery; Division of Radiation Oncology; University of British Columbia; Vancouver, BC Canada.
authors.forename: Maria T
authors.initials: MT
authors.lastname: Vlachaki
authors.affiliation: Trev and Joyce Deeley Research Centre; Victoria, BC Canada ; Department of Biochemistry and Microbiology; University of Victoria; Victoria, BC Canada.
authors.forename: Julian J
authors.initials: JJ
authors.lastname: Lum
keywords: androgen deprivation therapy; biochemical failure; external beam radiation therapy; prostate cancer; tumor-associated autoantibody
references.citation: Cancer Cell. 2005 May;7(5):411-23
references.pmid: 15894262
references.citation: Clin Cancer Res. 2007 Mar 1;13(5):1493-502
references.pmid: 17332294
references.citation: Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e713-9
references.pmid: 21277102
references.citation: Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
references.pmid: 16798415
references.citation: Cancer Cell. 2010 Feb 17;17(2):121-34
references.pmid: 20138013
references.citation: J Immunother. 2005 May-Jun;28(3):268-75
references.pmid: 15838384
references.citation: J Exp Med. 1998 Apr 20;187(8):1349-54
references.pmid: 9547346
references.citation: Clin Cancer Res. 2011 Mar 15;17(6):1571-81
references.pmid: 21159885
references.citation: Lancet Oncol. 2010 Nov;11(11):1066-73
references.pmid: 20933466
references.citation: Cancer Immunol Immunother. 2000 Jan;48(10):541-9
references.pmid: 10630306
references.citation: Immunol Rev. 2007 Dec;220:47-59
references.pmid: 17979839
references.citation: Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70
references.pmid: 11734652
references.citation: Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1397-404
references.pmid: 21665379
references.citation: J Biomed Biotechnol. 2011;2011:454861
references.pmid: 21197272
references.citation: Clin Cancer Res. 2010 Aug 1;16(15):4046-56
references.pmid: 20562209
references.citation: Nat Rev Immunol. 2010 Aug;10(8):580-93
references.pmid: 20651745
references.citation: Clin Cancer Res. 2012 Sep 1;18(17):4522-5
references.pmid: 22761465
references.citation: Curr Oncol. 2010 Sep;17 Suppl 2:S18-24
references.pmid: 20882127
references.citation: Nature. 2010 Mar 11;464(7286):302-5
references.pmid: 20220849
references.citation: J Immunol. 2003 Jun 15;170(12):6338-47
references.pmid: 12794167
references.citation: Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):43-9
references.pmid: 19570619
references.citation: Can J Urol. 2000 Feb;7(1):937-43
references.pmid: 11121249
references.citation: Int J Cancer. 2009 Dec 15;125(12):2871-8
references.pmid: 19554630